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INTRODUCTION
For intensive care medicine, significant advances in care have been limited in recent years. A
wealth of randomized clinical trials and a wide range of new protocols have yielded a wealth of
understanding but have not created the next-generation care hoped for. As a result, a “less is more”
perspective is growing in the field. This opinion article looks to the field of economics for lessons
in how we might consider changing perspective to develop and assess new approaches to care.
Current approaches to major forms of care in the intensive care unit (ICU) have stagnated,
increasingly complex patients with multiple co-morbidities have resulted in increased use of
resources, cost and risk of complications. Growing fear of iatrogenic complications has led to a
“less is more” approach to new care (1–3). The major hurdle to overcome is the increase in negative
outcomes, which seem to regularly arise with more aggressive approaches to care seen in a range
of randomized clinical trials in the last two or more decades. This analysis takes an outside the box
approach, with lessons from the field of Economics, to assess the situation and make some bold
proposals, in the interest primarily of stimulating “creative tension” in the field as to considering
the way forward.
COST-BENEFIT ANALYSIS, SO-CALLED FAT-TAILED RISK, AND
MEDICINE
A great deal of medical care treatment, perhaps particularly in the intensive care unit (ICU), can
be seen as decision making under uncertainty. An economist might broadly define this process as
assessing the potential value of the investment now vs. alternative outcome risks in the future, and
discounting the “cost” of the outcome accordingly. Discounting adjusts the costs and outcomes of
spending or interventions to account for investment benefits in delaying some or all of the cost of a
treatment (4). The underlying issue is to determine how much to invest now – cost-benefit analysis
(CBA) in simple. Thus, the question of what choice to make should be based on the relative “cost”
of mistakes and their discounted cost.
However, the efficacy of CBA has been recently questioned based on its use in climate change
analysis, challenged by Weitzman’s “Dismal Theorem” (5). Weitzman used this theorem to show
how traditional CBA could break down in issues like climate change, where avoiding a catastrophic
future would demand an infinite investment now. By analogy, in the ICU, the ultimate cost to
the patient is death, which would necessitate infinite investment in care using traditional CBA.
However, such infinite investment, despite the actual high costs of critical care, is not typically
made. This outcome demonstrates the fragility of CBA in the face of catastrophic or “fat tailed”
risk, which occurs when catastrophic events can occur with non-negligible likelihood, no matter
how remote the chance. More succinctly, the tail of the probability (of occurrence) distribution is
“fat” and has non-negligible likelihood.
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So-called “fat-tailed risk” arises from the formal definition of
the Dismal Theorem noting society has an infinite or undefinable
expected loss from very high consequence, but relatively very
low-probability events. The infinite cost makes it impossible
to calculate a present value to invest now to avoid it and
thus no discount rate can apply to make a decision between
options. The opposite, given human behavior, also arises, where
low consequence, higher probability events in future are overly
discounted and assumed to have a much lower or negligible
impact and cost today due to a range of factors (6, 7).
More specifically, decision making for clinical staff and family
is difficult, when we do not understand and cannot calculate
the risks and thus value of a given treatment, when death or an
unlikely event associated with increased mortality is a possible,
albeit unlikely outcome. More importantly, the opposite case
can also hold, where the risk of death or a negative outcome is
assumed to be lower than is actually the case, and so actions may
not be taken, the result of which are harmful to the patient. These
“poor” choices or difficult decisions are a result of underlying
uncertainty in patient response to care and thus in outcome, and
in particular of our inability to quantify them to more optimally
guide decision making and risk assessment in medical care, and
in critical care in particular.
This difficult compromise can lead to poor choices, in both
economics, but also as posited here, in medical decision-making
– all complicated by the underlying uncertainty of what might
occur in future, and the inability to properly assess underlying
risk of both very unlikely, and more likely, events.
ANALOGIES IN ICU MEDICINE
One clear, highly debated analogy in intensive care unit (ICU)
medicine arises from the debate around glycemic control
(GC) (8). Beyond potential benefit and the high difficulty in
providing safe, effective GC for all patients (9–11), the risk
of hypoglycemia—a potentially catastrophic event in terms
of outcome risk of death (12–16)—is offset by the risk of
permissive hyperglycemia from higher targets (17) and associated
glycemic variability (18–21), which have much lower perceived
relative risks, but are also associated with increased mortality.
Thus, economically, there is failure to control or invest in
GC given the so-called fat-tailed risk of hypoglycemia, where
no current investment seems able to ameliorate the problem,
and the opposite case also holding, where the risk of death
due to permissive poor GC increases the risk of death due to
underestimating the risk (over discounting).
This approach would provide an acceptable trade-off if
there was no possibility to obtain good control, safe from
hypoglycemia. Equally, the much lower (relative) and highly
discounted perceived risk of hyperglycemia for ICU patients
accepted in this trade-off clashes with the actual, higher relative
risk observed (22–26). In contrast, emerging personalized,
model-based GC approaches can provide safe, effective control
with reduced hypoglycemia (1–2% of patients) (27–29), and
emerging glucose sensing technologies offer further safety
increases (30).
However, in short, there remains a tendency to “invest
nothing,” and thus to minimal GC, to avoid the (now
manageable) fat-tailed catastrophic risk of hypoglycemia.
Concomitantly, there is thus also the resulting tendency to accept
relatively permissive levels of hyperglycemia by under-valuing
and over-discounting its negative effects and increased risk of
death. These choices and resulting outcome match well-known
and increasingly well-accepted economic observations and
human behaviors.
However, the “Dismal Theorem” is an “impossibility theorem”
and it does not tell you what you should do instead (31).
Relevant to the position made here, Weitzman was quoted: “We
desperately need more information about what’s going on in these
tails. It’s not the median values that are gonna kill us” (32). While
he said this concerning climate change, it could be equally applied
to many risks and choices made in ICU medicine, not just GC.
More directly, if we could quantify uncertainty and variability
in response to care, we could appropriately assess the risk, and
choose, economically speaking, the right discount rate to assess
whether (or not) to “invest” in more aggressive care.
The trade-off between these types of risk can be found in
many core ICU therapies. Mechanical ventilation has the trade-
off between the sudden impact of barotrauma or volutrauma
vs. the “slow” damage of increased inspired oxygen settings
when setting PEEP or tidal volume (33). Thus, quantifying
the risk, via new metrics or personalized models, would
allow the proper assessment of patient response and thus
whether (or not) to provide more aggressive ventilation settings,
which if done incorrectly increase the risk of cost, length
of stay, and mortality. Fluid resuscitation therapy faces a
similar contradiction between providing more input to support
circulatory and cardiac function, and the ongoing risk of
the therapy itself to patient outcome (34, 35). Quantifying
responsiveness to fluid resuscitation therapy is a “holy grail”
of ICU research, as quantifying the response would reduce
the risk and make it manageable. In all cases, difficulty arises
from the neither knowing, quantifying nor managing the risk
of outlying, harmful patient responses to care due to inter- and
intra- patient variability.
THE PROBLEM OF OUTLIERS,
VARIABILITY AND RISK
In general, many therapy approaches in randomized trials target
median or mean behaviors, the central tendency of a cohort.
However, they often fail to account for outliers or are unable to
achieve these median goal targets for all or nearly all patients.
Equally, those outlying events and patients can twist therapy
targets due to their high risk of negative impact, such as
hypoglycemia in GC. These outcomes suggest risk of behaviors
for a therapy, rather than outcome, should be primary targets,
particularly where fat-tailed risks can be quantified andmanaged.
Specifically, new approaches should seek to eliminate or
directly manage outliers as they constitute the fat-tailed risk and
are where both clinical and economical costs reside. This risk-
based approach focuses less on achieving a target and more
on minimizing any harm from care. It thus focuses on the
knowing and managing the “tails” of the distribution of possible
patient responses, rather than the central tendency or expected
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FIGURE 1 | Schematic example of risk-based vs. typical approaches. (A) When distributions are unknown and median or central tendency values are targeted all
distributions are centered together. A wide or fat-tailed distribution of response due to patient variability can create significant risk of being too low or too high
compared to a desired range. (B) When the distribution and the tails in particular are known, then a set threshold of risk (5%) of being too low (or high) can be set and
used to guide care, effectively shifting the distributions to a set lower bound in the example shown, and allowing the remainder of the distribution to fall where it may.
values, and in doing so might provide the means to develop
therapies providing safe, effective care for virtually all patients.
Overall, understanding and management of more immediate
risks can allow better CBA and decision-making when it comes
to evaluating interventions.
Figure 1 schematically shows how knowledge of potential
variability in patient response can be used in a risk-based
approach. When the distribution is unknown the response can
be more or less variable, creating undesirable risk of a patient
outcome response being too low (or too high) if the distribution
is fat-tailed or wide. However, if the distribution is known, then
care choices can be predicated on this knowledge, allowing a
set threshold (5% in Figure 1) of risk in response to care. The
analogy in the glycemic control case would be blood glucose
below 4.0 mmol/L (72 mg/dL), associated with increasing risk.
Given the focus on uncertainty in Weitzman’s work and in
CBA in general, as applied economically, there is significant
strong analogy to the practice of medicine. Using GC as a “straw
man” it is particularly applicable to the design and evaluation
of new therapy approaches, where randomized trials are often
confounded by the complexity, multiple factors, and uncertainty
governingmajor outcomes in ICU patients and thus fail to deliver
clear direction to the field (2, 3). Thus, the ability to quantify and
directly manage patient variability and risk in care would provide




Determining the distribution of risk or patient variability
can be done using data, which is more and more available,
both directly in statistical or stochastic models (36–38) or
via a range of emerging artificial intelligence and/or deep
learning methods (39). In fact, managing patient variability
is an emerging field reflected in a range of recent research.
Specifically in areas like new drug development methods,
assessing differences between in response to care due to
differences in race or sex, the use of a range of “omics” (e.g.,
proteomics, genomics) to better classify and target care, and
in the broader use of “big data” and machine learning to
everything from personalizing care to early warning alarms and
other applications.
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All of these approaches are emerging means to better classify
patients and their potential needs, risks and variable responses
(to care), sharing the common trait of bringing risk management
into dosing and care. Doing so inherently creates increasingly
personalized protocols. The act of personalizing care, whether
done at the bedside or via algorithms and technology, is
about managing patient-specific behaviors and responses to care
outside the mean, median or central tendency, otherwise there
would be no point to the effort. It is thus about giving all patients
the best opportunity to respond like the expected target patient –
inherently then, it is about risk reduction.
Once potential or actual variability and its risk is quantified
in some way, it can be directly managed in care. Currently, only
one glycemic control protocol takes such an approach in critical
care, using a direct model-based approach to cohort variability
to minimize hypoglycemia and provide consistent care across
a range of cohorts (27). It shows the potential of this type of
approach, vs. a targeted glycemia approach, and as data increases,
greater resolution and personalization should be realized.
Hence, it is important to quantify variability for use in
managing patient care to reduce the risk of outlier responses and
to thus create ever narrower ranges of overall patient response
to care. However, risk reduction is often a secondary outcome at
best in many studies, with the primary focus being performance
to desired clinical outcomes. If the future of ICU care is on
personalizing care, and thus on directly managing and reducing
risk, then it might be time to consider risk quantification,
management and reduction as the primary goal in developing
new approaches to care.
Surely if the risk of care can be managed and reduced,
particularly in current care, then the increased personalization
of care might help overcome a current stagnation in improving
outcomes (and cost).
A BOLD PROPOSITION?
As a result, this opinion and commentary puts forward two
main propositions:
• Greater emphasis should be put on risk-based dosing, rather
than on target-based dosing to minimize the likelihood of
both fat-tailed and perceived lesser risks. In GC, dosing on
risk to simultaneously minimize the relative risks of both
hypoglycemia and permissive hyperglycemia. In short, dosing
to minimize outliers rather than achieve a desired specific
target or outcome.
• There needs to be far greater weight in clinical research put
on evidence quantifying relative risks of choices in core ICU
therapies, where large randomized trials on overall outcomes
struggle given all the other uncertainties and complexity in the
ICU patient (3).
More succinctly, when developing and evaluating protocols or
approaches, like policy levers and choices in economics, risk-
based and optimized decision making should be of concern over
targeted median values and outcome focused approaches. This
risk-based approach is not today’s care, but should be tomorrow’s.
DISCUSSION
The field of intensive care medicine faces significant challenges
from increasing demographics and complexity of patients.
However, it has seen far less significant advances in care
compared to the level and intensity of research directed at the
core problems it faces in care. This outside the box analysis
examines the issue and through a set of “bold proposals” suggests
the need for much greater quantification and direct management
of risk in clinical care, treating outliers rather than seeking targets
for the “middle.” It thus suggests re-examining how clinical
evidence is viewed and redesigning how clinical trial goals are
designed in an effort to address issues with variability and risk,
which are currently under-served or ignored.
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